Grantham Mayo Van Otterloo & Co. LLC Buys Shares of 17,192 Medpace Holdings, Inc. (NASDAQ:MEDP)

Grantham Mayo Van Otterloo & Co. LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 17,192 shares of the company’s stock, valued at approximately $5,712,000. Grantham Mayo Van Otterloo & Co. LLC owned approximately 0.06% of Medpace as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Pallas Capital Advisors LLC grew its position in Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after purchasing an additional 2,101 shares in the last quarter. Barclays PLC increased its position in shares of Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after acquiring an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after acquiring an additional 844 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Medpace by 10.0% during the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock worth $14,722,000 after acquiring an additional 4,023 shares in the last quarter. Finally, SYM FINANCIAL Corp acquired a new position in Medpace during the fourth quarter valued at approximately $320,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of MEDP stock opened at $287.11 on Monday. The company has a market capitalization of $8.75 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 3.81 and a beta of 1.45. Medpace Holdings, Inc. has a 52 week low of $282.42 and a 52 week high of $459.77. The company has a 50-day simple moving average of $331.56 and a 200 day simple moving average of $337.32.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MEDP. Robert W. Baird upped their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target on the stock. Finally, Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.